Caplin Point Laboratories (524742) Q2 26/27 earnings summary

Executive summary

• H1 FY27 total revenue reached ₹1,307.04 crore, up 19.1% YoY; EBITDA was ₹503.54 crore, up 19.8%, and PAT was ₹361.42 crore, up 16.2%.

• H1 priorities include expanding regulated-market sales and CSU, strengthening manufacturing and API integration, and growing Latin American distribution through asset-light and asset-heavy models.

Financial highlights

• Q2 FY27 revenue from operations was ₹629.84 crore, up 17.9% YoY; EBITDA rose 16.8% to ₹256.5 crore, PBT 15.8% to ₹232.83 crore, and PAT 13.8% to ₹182.35 crore.

• H1 FY27 gross profit was ₹756.33 crore, up 18.4% YoY; EBIT increased 18.8% to ₹458.43 crore.

• H1 US business revenue was ₹271 crore, up 22.8% YoY; Caplin Steriles USA sales exceeded FY26 sales.

• Standalone H1 revenue was ₹444.83 crore, PBT ₹317.64 crore and PAT ₹250.89 crore, versus ₹357.75 crore, ₹241.46 crore and ₹188.48 crore in H1 FY26.

Outlook and guidance

• CSU expects FY27 revenue and profitability to double; management is targeting 20%-25% U.S. business growth, with 10 additional U.S. launches planned for FY28.

• More than 60 products are planned for filing in non-U.S. markets over 18 months; meaningful revenue is expected in FY27/FY28.

• COL-II construction is targeted for completion by August 2027; meaningful revenue is expected in FY28-29 and beyond, following transfers, studies, filings and inspection.

• Amaris Clinical expansion to 120 beds is expected by FY27-end; oncology API facility completion is targeted for CY27, with DMF filings planned afterward.

• Mexico liquid-orals and IV-fluid manufacturing is planned for export into Central America; facility completion may take 2-3 years.